Qure.ai and Therapixel Collaborate to Enhance Breast Cancer Detection with AI

Qure.ai, a leading medical AI imaging company, has partnered with French firm Therapixel to distribute their MammoScreen® technology globally. MammoScreen® uses AI to enhance early breast cancer detection, crucial for successful treatment in over 90% of cases. It aids radiologists in reading a large number of mammography exams, leading to improved detection rates and faster reading times, benefiting both experienced and less experienced radiologists.  

By integrating MammoScreen® into its portfolio, Qure.ai now offers a comprehensive imaging AI solution covering lung and breast cancer, among other areas. The cutting-edge AI technology assists radiologists in faster and more accurate diagnosis across various healthcare workflows and locations.  

This collaboration aims to improve breast cancer detection accuracy and efficiency, leading to earlier diagnoses and better patient outcomes globally. Recent studies have shown that MammoScreen® significantly enhances radiologists' performance in detecting cancers and reducing reading time, making it a valuable addition to the medical community's efforts in combating breast cancer.